About Azalea Therapeutics
Azalea Therapeutics is a Berkeley, California-based biotechnology company redefining precision genomic medicines in vivo. Its proprietary Enveloped Delivery Vehicle (EDV) platform delivers transient CRISPR-Cas9 cargo to specific cells in the body for site-specific genome editing, enabling in vivo CAR-T cell therapies for cancer, autoimmune disease, and genetic disorders. The company's approach eliminates the need for complex ex vivo manufacturing by engineering therapeutic T cells directly inside each patient.
Company details
Funding
Total raised
$82M
Last stage
Series A
Investors
Founders
Jenny Hamilton
Ph.D., spearheaded the EDV technology in the Doudna Lab at UC Berkeley; co-founder, president and chief executive officer of Azalea Therapeutics.
LinkedInJennifer Doudna
Ph.D., Nobel laureate in chemistry (2020), Li Ka Shing Chancellor's Chair at UC Berkeley, founder of the Innovative Genomics Institute.
Michael Fischbach
Ph.D., Liu (Liao) Family Professor of Bioengineering at Stanford University, institute scholar of Stanford ChEM-H.
Justin Eyquem
Ph.D.; associate professor of medicine in the Division of Hematology and Oncology at UCSF; affiliate investigator at Gladstone Institutes; member of the Parker Institute for Cancer Immunotherapy.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.